β Scribed by Michael Jones; Brad Schenkel; Julie Just; Lesley Fallowfield
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Anemia and decreased health-related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining R
Anemia, a commonly occurring morbidity in patients with cancer, often leads to diminished quality of life (QOL). Numerous clinical trials have shown that epoetin alfa treatment improves hematologic and QOL variables in cancer patients. The clinical trial analysis reported here was performed to asses
## Background: Hemoglobin increases have been associated with quality of life (qol) improvements in anemic cancer patients treated with epoetin alfa, but intervention generally has been reserved for symptomatic anemia or hemoglobin < 10 g/dl. relationships among hemoglobin, functional status, and p
## Abstract DOI 10.1002/cncr.11430